The Cost Of A Cure: Gilead Exec Outlines Factors In Sovaldi’s Pricing
This article was originally published in The Pink Sheet Daily
Gilead Science Executive VP Gregg Alton defended Sovaldi’s pricing at an AEI event July 11, the same day Senators Wyden and Grassley sent a letter requesting detailed information on the company’s investment in the drug and how it set the price.
You may also be interested in...
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.
DeRoyal’s DeBusk urges a focus on rebates, while Brookings' Ginsburg wants a focus on design, not savings per se, as MedPAC discusses restructuring the Part D design to better accommodate current market dynamics. Formal recommendations to Congress may be approved in the spring.